News summary

Onward Therapeutics Closes USD 28 Million Series B Financing

Source: Startupticker.ch • Published: 19 Nov 2026, 00:00

Summarized by Masters of Longevity from Startupticker.ch.

Clinical-stage oncology biotech closed USD 28 million to fund trials and R&D.

Onward Therapeutics Closes USD 28 Million Series B Financing
Key Takeaways
  • Onward Therapeutics raised about USD 28 million in Series B.
  • Proceeds will fund clinical programs, manufacturing, and early R&D.
  • Plans include expanding Taiwan operations and pursuing a Taipei listing.
Read the full article at Startupticker.ch ↗

Continue exploring

Recommended MoL Picks

MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickNucleotides and Longevity: Is the Evidence Ready?They help build DNA and keep cells working. Early human studies make nucleotide supplements interesting—but leave important questions about healthy ageing unanswered. Yet.